Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other financing activities: 2014-2025

Historic Other financing activities for Theravance Biopharma (TBPH) over the last 9 years, with Sep 2025 value amounting to $678,000.

  • Theravance Biopharma's Other financing activities rose 70.78% to $678,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 million, marking a year-over-year decrease of 2.53%. This contributed to the annual value of $2.7 million for FY2024, which is 6.36% up from last year.
  • Theravance Biopharma's Other financing activities amounted to $678,000 in Q3 2025, which was up 34.79% from $503,000 recorded in Q2 2025.
  • Theravance Biopharma's Other financing activities' 5-year high stood at $5.6 million during Q1 2021, with a 5-year trough of $347,000 in Q2 2022.
  • Over the past 3 years, Theravance Biopharma's median Other financing activities value was $528,000 (recorded in 2024), while the average stood at $655,909.
  • Its Other financing activities has fluctuated over the past 5 years, first surged by 131.61% in 2021, then slumped by 74.11% in 2022.
  • Over the past 5 years, Theravance Biopharma's Other financing activities (Quarterly) stood at $455,000 in 2021, then slumped by 71.04% to $662,000 in 2022, then dropped by 22.66% to $518,000 in 2023, then climbed by 1.93% to $528,000 in 2024, then skyrocketed by 70.78% to $678,000 in 2025.
  • Its Other financing activities stands at $678,000 for Q3 2025, versus $503,000 for Q2 2025 and $874,000 for Q1 2025.